Recent Updates in Bispecific Therapies for Patients With Relapsed/Refractory Multiple Myeloma

home / around-the-practice / recent-updates-in-bispecific-therapies-for-patients-with-relapsed-refractory-multiple-myeloma

Alfred Garfall, MD; Omar Nadeem, MD; Naresh Bumma, MD; and Surbhi Sidana, MD,explore the evolving therapeutic landscape of relapsed/refractory multiple myeloma, including bispecific antibodies, real-world outcomes across treatment settings, optimal sequencing strategies after CAR T progression, and long-term efficacy data from key clinical trials like MajesTEC-1.

Brief Overview of Therapeutic Landscape for R/R MM

EP. 1: Brief Overview of Therapeutic Landscape for R/R MM

Alfred Garfall, MD;Omar Nadeem, MD;Naresh Bumma, MD;Surbhi Sidana, MD
December 19th 2024

Panelists discuss how emerging therapies like bispecific antibodies, chimeric antigen receptor (CAR) T cells, and novel drug combinations are reshaping treatment options for patients with relapsed/refractory multiple myeloma (R/R MM) who have exhausted standard approaches.